Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07412470
PHASE2/PHASE3

A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

Sponsor: Sanofi

View on ClinicalTrials.gov

Summary

The purpose of this open-label, randomized, active-comparator-controlled study is to determine the efficacy and safety of frexalimab subcutaneous administrations up to 5 years compared to tacrolimus capsules in adults undergoing kidney transplantation. Participants aged 18 to 70 years who have low-to-moderate immunologic risk of graft rejection and receive their first kidney transplant are eligible if they meet all inclusion and no exclusion criteria. Study details include: * The study and treatment duration will be up to approximately 5 years. * The number of visits will be approximately 38.

Official title: A Seamless Phase 2/3 Randomized, Open-label Study to Investigate Efficacy and Safety of Frexalimab Versus Tacrolimus in Adult Kidney Transplant Recipients

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

526

Start Date

2026-03-13

Completion Date

2033-08-15

Last Updated

2026-03-27

Healthy Volunteers

No

Interventions

DRUG

Frexalimab

Pharmaceutical form:Solution for injection-Route of administration:IV

DRUG

Frexalimab

Pharmaceutical form:Solution for injection-Route of administration:SC

DRUG

Tacrolimus

Pharmaceutical form:Capsule-Route of administration:Oral

DRUG

rabbit anti-thymocyte globulin

Pharmaceutical form:Solution for injection-Route of administration:IV

DRUG

mycophenolate mofetil

Pharmaceutical form:Tablet or capsule-Route of administration:Oral

DRUG

mycophenolate sodium

Pharmaceutical form:Tablet-Route of administration:Oral

DRUG

methylprednisolone

Pharmaceutical form:Solution for injection-Route of administration:IV

DRUG

prednisone

Pharmaceutical form:Tablet-Route of administration:Oral

Locations (2)

Investigational Site Number : 0360003

Sydney, Australia

Investigational Site Number : 1560001

Shanghai, China